Pharmena S.A. (WSE:PHR)

Market Cap	34.97M -10.3%
Revenue (ttm)	1.61M +146.5%
Net Income	-2.76M
EPS	-0.25
Shares Out	11.14M
PE Ratio	n/a
Forward PE	n/a
Dividend	0.85 (27.07%)
Ex-Dividend Date	n/a

Volume	4,698
Open	3.200
Previous Close	3.210
Day's Range	3.050 - 3.200
52-Week Range	2.500 - 4.320
Beta	0.56
Analysts	n/a
Price Target	16.10 (+416.03%)
Earnings Date	May 28, 2026

About Pharmena

Pharmena S.A. engages in the sale of dietary supplements in Poland and internationally. It also develops 1-MNA (PHR-701 program), a medical device for use in difficult-to-heal wounds. In addition, the company is involved in research and development of therapeutic applications of 1 MNA as an anti-inflammatory and anti-fibrotic drug; and research and development at pulmonary fibrosis, respiratory tract infections, including viral infections, COVID-19, inflammatory diseases, metabolic diseases and other therapeutic applications. Pharmena S.A. was ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 7
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: PHR

Financial Performance

In 2025, Pharmena's revenue was 1.58 million, an increase of 488.43% compared to the previous year's 268,000. Losses were -2.77 million, 119.4% more than in 2024.